Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature

Pathologic complete response (pCR) after NC has been consistently associated with improved outcomes. Residual DCIS after NC does not portray worse prognosis compared to complete eradication of all disease but has clinical implications regarding surgical management. We report a case of pCR of DCIS as...

Full description

Saved in:
Bibliographic Details
Main Authors: Sommer R. Gunia, Mita S. Patel, Eleftherios P. Mamounas
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Case Reports in Surgery
Online Access:http://dx.doi.org/10.1155/2012/454273
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850213112862474240
author Sommer R. Gunia
Mita S. Patel
Eleftherios P. Mamounas
author_facet Sommer R. Gunia
Mita S. Patel
Eleftherios P. Mamounas
author_sort Sommer R. Gunia
collection DOAJ
description Pathologic complete response (pCR) after NC has been consistently associated with improved outcomes. Residual DCIS after NC does not portray worse prognosis compared to complete eradication of all disease but has clinical implications regarding surgical management. We report a case of pCR of DCIS associated with invasive carcinoma in an HER-2 + tumor after NC plus trastuzumab despite persistence of malignant-appearing microcalcifications mammographically. A 41-year-old Caucasian female presented with a 4×4 cm mass in the right breast and a 2.5 cm right axillary node. Mammogram showed a 2.5 cm mass and a 12 cm area of linear pleomorphic, suspicious calcifications in the upper part of the breast. Core biopsy revealed invasive ductal carcinoma and DCIS associated with calcifications (ER 85%, PR 6%, Her2neu 3+ by IHC). Axillary node FNA was positive for malignancy. The patient received doxorubicin/cyclophosphamide (AC) → paclitaxel plus T with complete clinical and radiologic response but no significant change in the microcalcifications. Final pathology showed no residual invasive carcinoma or DCIS despite the presence of numerous ducts with microcalcifications. Documented eradication of DCIS has not been reported following NC when malignant-appearing calcifications persist and this observation may have important clinical implications regarding surgical management.
format Article
id doaj-art-8bb89686b74f4f53a79d960798d2a2ac
institution OA Journals
issn 2090-6900
2090-6919
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Case Reports in Surgery
spelling doaj-art-8bb89686b74f4f53a79d960798d2a2ac2025-08-20T02:09:11ZengWileyCase Reports in Surgery2090-69002090-69192012-01-01201210.1155/2012/454273454273Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of LiteratureSommer R. Gunia0Mita S. Patel1Eleftherios P. Mamounas2Department of Surgery, Affinity Medical Center, Massillon, OH 44646, USADepartment of Surgery, Akron General Medical Center, Akron, OH 44307, USACancer Center, Aultman Health Foundation, Canton, OH 44710, USAPathologic complete response (pCR) after NC has been consistently associated with improved outcomes. Residual DCIS after NC does not portray worse prognosis compared to complete eradication of all disease but has clinical implications regarding surgical management. We report a case of pCR of DCIS associated with invasive carcinoma in an HER-2 + tumor after NC plus trastuzumab despite persistence of malignant-appearing microcalcifications mammographically. A 41-year-old Caucasian female presented with a 4×4 cm mass in the right breast and a 2.5 cm right axillary node. Mammogram showed a 2.5 cm mass and a 12 cm area of linear pleomorphic, suspicious calcifications in the upper part of the breast. Core biopsy revealed invasive ductal carcinoma and DCIS associated with calcifications (ER 85%, PR 6%, Her2neu 3+ by IHC). Axillary node FNA was positive for malignancy. The patient received doxorubicin/cyclophosphamide (AC) → paclitaxel plus T with complete clinical and radiologic response but no significant change in the microcalcifications. Final pathology showed no residual invasive carcinoma or DCIS despite the presence of numerous ducts with microcalcifications. Documented eradication of DCIS has not been reported following NC when malignant-appearing calcifications persist and this observation may have important clinical implications regarding surgical management.http://dx.doi.org/10.1155/2012/454273
spellingShingle Sommer R. Gunia
Mita S. Patel
Eleftherios P. Mamounas
Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
Case Reports in Surgery
title Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
title_full Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
title_fullStr Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
title_full_unstemmed Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
title_short Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
title_sort pathologic complete response of her 2 neu positive invasive ductal carcinoma and ductal carcinoma in situ following neoadjuvant chemotherapy plus trastuzumab a case report and review of literature
url http://dx.doi.org/10.1155/2012/454273
work_keys_str_mv AT sommerrgunia pathologiccompleteresponseofher2neupositiveinvasiveductalcarcinomaandductalcarcinomainsitufollowingneoadjuvantchemotherapyplustrastuzumabacasereportandreviewofliterature
AT mitaspatel pathologiccompleteresponseofher2neupositiveinvasiveductalcarcinomaandductalcarcinomainsitufollowingneoadjuvantchemotherapyplustrastuzumabacasereportandreviewofliterature
AT eleftheriospmamounas pathologiccompleteresponseofher2neupositiveinvasiveductalcarcinomaandductalcarcinomainsitufollowingneoadjuvantchemotherapyplustrastuzumabacasereportandreviewofliterature